Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ...

Eligible patients can receive up to 70 per cent in subsidies for genetic tests, while MediShield Life coverage will be extended to selected risk-reducing surgical procedures.

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that it has ...

Abstract: In this paper, a new composite NDT testing sensor for boiler water wall tubes defect detection is designed which using a combination of the electromagnetic acoustic transducer (EMAT) method, ...

Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, ...

Abstract: The main aim of this study is to determine the effectiveness of a penetration testing tool, GyoiThon as a Machine Learning tool by conducting penetration tests on websites, including the ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only ...

Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line ...

SANTA CLARA, Calif., February 12, 2026--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code ...

Appellate Division Says NY Court System Violated Labor Laws in Implementing COVID-19 Testing Procedure The decision, from the Appellate Division, First Department, affirms a lower court ruling in ...